Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hutchison Medipharma Initiates Phase I Trials Of Cancer-fighting Candidate Sulfatinib In China

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - Chinese innovative drug developer Hutchison MediPharma has initiated Phase I clinical trials in China for its anti-cancer drug candidate, HMPL-012 (sulfatinib), the company said May 6

You may also be interested in...



China Builds Up Capability To Conduct Oncology First-In-Man Studies

SHANGHAI - Oncology clinical site operator South Texas Accelerated Research Therapeutics (START) is partnering with Fudan University Shanghai Cancer Center (FUSCC) and Cenova Venture Fund to open an oncology site in Shanghai to provide early-phase clinical services in China to support the many global and domestic pharma and biotech companies that are investing in more projects to target China's oncology market

China Builds Up Capability To Conduct Oncology First-In-Man Studies

SHANGHAI - Oncology clinical site operator South Texas Accelerated Research Therapeutics (START) is partnering with Fudan University Shanghai Cancer Center (FUSCC) and Cenova Venture Fund to open an oncology site in Shanghai to provide early-phase clinical services in China to support the many global and domestic pharma and biotech companies that are investing in more projects to target China's oncology market

Chinese Government Venture Firm Funds JV To Explore Early-stage Oncology Trials

SHANGHAI- Texas-based South Texas Accelerated Research Therapeutics recently announced that it will partner with Shanghai-based venture capital fund Cenova Ventures to form a joint venture to conduct early-stage oncology trials for pharma companies on both sides of the Pacific

Related Content

UsernamePublicRestriction

Register

LL1132247

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel